Med. Pro Praxi 2007; 3: 120-123 [Klin Farmakol Farm. 2006;20(1):26-29]

Profylaktická léčba migrény

MUDr. Rudolf Kotas Ph.D
Neonatologické oddělení, FN a LF UK, Plzeň

Migréna je běžně se vyskytující epizodická bolest hlavy. Komplexní léčba zahrnuje léčbu akutní ataky, která má za cíl úlevu od bolesti, a profylaktickou léčbu, která má snížit frekvenci, intenzitu a trvání atak. V tomto článku jsou v přehledu uvedeny klinický obraz, patofyzio­logie a profylaktická léčba migrény. Mezi profylaktické léky patří betablokátory, blokátory kalciových kanálů, antiepileptika, antagonisté serotoninu, antidepresiva a další profylaktika.

Keywords: migréna, patofyziologie, profylaktická léčba

Published: March 1, 2007  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kotas R. Profylaktická léčba migrény. Med. praxi. 2007;4(3):120-123.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Stewart WF, Lipton RB, Celentano DD, Reed ML. Prevalence of migraine headache in the United States. Relation to age, income, race, and other sociodemographic factors. JAMA 1992; 267: 64-69. Go to original source... Go to PubMed...
    2. Davidoff RA. Migraine: manifestations, pathogenesis and management. Philadelphia: F.A. Davis Company, 1995: 375.
    3. Kotas R. Moderní trendy v patofyziologii migrény. Prakt Lék 1999; 79: 498-500.
    4. Kotas R, a kol. Migréna - patofyziologie a léčba. Praha: Maxdorf, 2001: 195.
    5. Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders (2nd Edition). Cephalalgia 2004 (Suppl 1); 24: 1-160.
    6. Lauritzen M. Spreading depression and migraine. Pathol Biol Paris 1992; 40: 332-337. Go to PubMed...
    7. Leao AAP. Spreading depression of activity in cerebral cortex. J Neurophysiol 1944; 7: 332-337. Go to original source...
    8. Welch KMA. Migraine. A biobehavioral disorder. Arch Neurol 1987; 44: 323-327. Go to original source... Go to PubMed...
    9. Lauritzen M, Olesen J. Regional cerebral blood flow during migraine attacks by Xenon133 inhalation and emission tomography. Brain 1984; 107: 447-461. Go to original source... Go to PubMed...
    10. Woods RP, Iacoboni M, Mazziotta JC. Bilateral spreading cerebral hypoperfusion during spontaneous migraine headache. N Engl J Med 1994; 331: 1689-1692. Go to original source... Go to PubMed...
    11. Goadsby PJ, Edvinson L, Ekman R. Release of vasoactive peptides in the extracerebral circulation of man and the cat during activation of the trigeminovascular system. Ann Neurology 1988; 23: 193-196. Go to original source... Go to PubMed...
    12. Moskowitz MA. The neurobiology of vascular head pain. Ann Neurol 1984; 16: 157-168. Go to original source... Go to PubMed...
    13. Fozard JR. 5-hydroxytryptamine and nitric oxide: the causal relationship between two endogenous precipitants of migraine. In: Sander M, Ferrari M, Harnett S, eds. Migraine. Pharmacology and genetics. London, Glasgow, Weinheim, New York, Tokyo, Melbourne, Madras: Chapman and Hall, 1996: 167-179.
    14. Thomsen LL, Olesen J. The role of nitric oxide in migraine pain. In: Sander M, Ferrari M, Harnett S, eds. Migraine. Pharmacology and genetics. London, Glasgow, Weinheim, New York, Tokyo, Melbourne, Madras: Chapman and Hall, 1996:154-166.
    15. Ferrari MD, Saxena PR. 5-HT1 receptors in migraine pathophysiology and treatment. Eur J Neurology 1995; 2: 5-21. Go to original source... Go to PubMed...
    16. Silberstein SD. Preventive treatment of migraine: an overview. Cephalalgia 1996; 17: 67-72. Go to original source... Go to PubMed...
    17. Waberžinek G. Migréna - diagnostika a léčba. Praha: Triton, 2003: 158.
    18. Donáth V. Preventivná liečba migrény. Neurologie pro praxi 2003; 4: 63-66.
    19. Goadsby PJ. How do the currently used prophylactic agents work in migraine? Cephalagia 1997; 17: 85-92. Go to original source... Go to PubMed...
    20. Ramadan NM, Schultz LL, Gilkey SJ. Migraine prophylactic drugs: proof of efficacy, utilization and cost. Cephalalgia 1997; 17: 268-271. Go to original source... Go to PubMed...
    21. Diamond S, Kudrow L, Stevens J, Scharpiro DB. Long-term study of propranolol in the treatment of migraine. Headache 1982; 22: 268-271. Go to original source... Go to PubMed...
    22. Brumel B. Migraine: A pharmacological review with newer options delivery modalities. Neurology 1994; 44 (Suppl 3): S13-S17. Go to PubMed...
    23. Kangasniemi P, Andersen AR, Anderson PG. Classic Migraine. Effective prophylaxis with metoprolol. Cephalalgia 1987; 7: 231-238. Go to original source... Go to PubMed...
    24. Ryan RE, Ryan RE, Sudilovsky A. Nadolol: its use in the prophylactic treatment of migraine. Headache 1983; 23: 26-31. Go to original source... Go to PubMed...
    25. Sorensen PS, Hansen K, Olesen J. A placebo-controlled, double-blind, cross-over trial of flunarizine in common migraine. Cephalalgia 1986; 6: 7-14. Go to original source... Go to PubMed...
    26. Centoze V, Magrone D, Vino M. Flunarizine in migraine prophylaxis: efficacy and tolerability of 5mg and 10mg dose levels. Cephalalgia 1990; 10: 17-24. Go to original source... Go to PubMed...
    27. Olesen J. Calcium antagonists in migraine and vertigo. Possible mechanisms of action and review of clinical trials. Eur Neurol 1990; 30 (Suppl 2): 31-34. Go to original source... Go to PubMed...
    28. Nuti A, Lucetti C, Pavese N, Dell´Angello G, Rossi G, Bonucceli U. Long term follow-up after flunarizine or nimodipine discontinuation in migraine patiens. Cephalalgia 1996; 16: 337-340. Go to original source... Go to PubMed...
    29. Waberžinek G, Keller O, Marková J. Bolesti hlavy - současná klasifikace, diagnóza a léčba. Čes a Slov Neurol Neurochir (Tematická příloha) 1999; 62: 1-15.
    30. Cutrer FM, Limmroth V, Moskowitz MA. Possible mechanisms of valproate in migraine prophylaxis. Cephalalgia 1997; 17: 93-100. Go to original source... Go to PubMed...
    31. Cutrer FM, Limmroth V, Ayata G, Moskowitz MA. Attenuation by valproate of c-fos immunoreactivity in trigeminal nucleus caudalis induces by intracisternal capsaicin. J Pharmacol 1995; 3:199-204. Go to original source...
    32. Stoper RJ, Goadsby PJ. Topiramate inhibits trigeminovascular neurons in the cat. Cephalalgia 2004; 24: 1049-1056. Go to original source... Go to PubMed...
    33. Kotas R. Antiepileptika v profylaxi migrény. Bolest 2005; 8-13.
    34. Mathew NT, Saper JR, Silberstein SD, et al. Migraine prophylaxis with divalproex. Arch Neurol 1995; 52: 281-286. Go to original source... Go to PubMed...
    35. Klapper J. Divalproex podium in migraine prophylaxis: a dose-controlled study. Cephalalgia 1997; 17: 103-108. Go to original source... Go to PubMed...
    36. Silberstein SD. Divalproex sodium in headache - literatue review and clinical guidelines. Headache 1996; 36: 547-555. Go to original source... Go to PubMed...
    37. Brandes JL, Saper JR, Diamond M, Couch JR, Lewis DW, Schmidt J, Neto W, Schwabe S, Jacobs D. Topiramate for Migraine Prevention. JAMA 2004; 291: 965-972. Go to original source... Go to PubMed...
    38. Silberstein SD, Neto W, Schmidt J, Jacobs D. Topiramate in Migraine Prevention. Arch Neurol 2004; 61: 490-495. Go to original source... Go to PubMed...
    39. Diamond S, Medina TL. Headaches. Clinical Symposia 1989; 41: 2-32. Go to PubMed...
    40. Medová E, Kalvach P. Léčba migrény. In: Medová E, Kalvach P. Migréna - minimum pro praxi. Praha: Triton, 1998: 108-126.
    41. Diamond S, Millstein E. Current concepts of migraine therapy. J Clin Pharmacol 1988; 28: 193-199. Go to original source... Go to PubMed...
    42. Antony M, Lance TW. Current Concepts in the Pathogenesis and Interval Treatment of Migraine. Drug 1972; 3: 153-158. Go to original source... Go to PubMed...
    43. Speight TM, Avery GF. Pizotifen (BC-105): A Review of its Pharmacological Properties and its Therapeutic Efficacy in Vascular Headaches. Drugs 1972; 3: 159-203. Go to original source... Go to PubMed...
    44. Gomersall JD, Stuart A. Amitriptyline in migraine prophylaxis. Changes in pattern of attacks during a controlled clinical trial. J Neurol Neurosurg Psychiatry 1973; 36: 684-690. Go to original source... Go to PubMed...
    45. Couch JR, Hassanein RS. Amitriptyline in migraine prophylaxis. Arch Neurol 1979; 36: 695-699. Go to original source... Go to PubMed...
    46. Yiegler DK, Hurwitz A, Hassanein RS, Kodanaz HA, Preskorn SH, Mason J. Migraine prophylaxis. A comparison of propranolol and amitriptyline. Arch Neurol 1987; 44: 486-489. Go to original source... Go to PubMed...
    47. Mastík J. Migréna - nová mezinárodní klasifikace a moderní léčebné postupy. Neurologie pro praxi 2004; 5: 79-83.
    48. Peikert A, Wilimzig C, Kohne-Volland R. Prophylaxis of migraine with oral magnesium: results from a prospective, multi-center, placebo-controlled and double-blind randomized study. Cephalalgia 1996; 16: 257-263. Go to original source... Go to PubMed...
    49. Schoenen J, Jacquy J, Lenaerts M. Effectiveness of high-dose riboflavin in migraine prophylaxis. A randomized controlled trial. Neurology 1998; 50: 466-470. Go to original source... Go to PubMed...
    50. Gobel H, Jost WH. Botulinum Toxin in the Treatment of Migraine. In: Jost WH. Botulinum Toxin in Painful Diseases. Basel, Freiburg, Paris, London, New York, Bangalore, Bangkok, Singapure, Tokyo, Sydney: Karger, 2003: 102-125. Go to original source...
    51. Ashkenazi A, Silberstein SD. The evolving management of migraine. Curr Opin Neurol 2003; 16, 341-345. Go to original source... Go to PubMed...

    Return to the content


    Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.